Abstract
The co-inhibitory receptor programmed cell death (PD)-1, expressed by immune effector cells, is credited with a protective role for normal tissue during immune responses, by limiting the extent of effector activation. Its presently known ligands, programmed death ligands (PD-Ls) 1 and 2, are expressed by a variety of cells including cancer cells, suggesting a role for these molecules as an immune evasion mechanism. Blocking of the PD-1-PD-L signaling axis has recently been shown to be effective and was clinically approved in relapsed/refractory tumors such as malignant melanoma and lung cancer, but also classical Hodgkin's lymphoma. A plethora of trials exploring PD-1 blockade in cancer are ongoing. Here, we review the role of PD-1 signaling in lymphoid malignancies, and the latest results of trials investigating PD-1 or PD-L1 blocking agents in this group of diseases. Early phase studies proved very promising, leading to the clinical approval of a PD-1 blocking agent in Hodgkin's lymphoma, and Phase III clinical studies are either planned or ongoing in most lymphoid malignancies.
Citations
Feb 9, 2018·Journal of Clinical and Experimental Hematopathology : JCEH·Ayako SakakibaraKei Kohno
Aug 11, 2018·Pathology International·Ayako SakakibaraShigeo Nakamura
Oct 3, 2018·Blood·Monika HerrmannMarion Subklewe
Jan 3, 2019·Pathology International·Yuka SuzukiKei Kohno
May 6, 2020·Cancer Medicine·Yuka SuzukiAkira Satou
Jul 3, 2020·Cells·Massimo Giuliani, Alessandro Poggi
Aug 13, 2020·Pathology International·Emiko TakahashiShigeo Nakamura
Aug 27, 2018·Journal of Cellular Biochemistry·Hui LiYao-Zhou Tian
Oct 24, 2018·Cytometry. Part B, Clinical Cytometry·Ravnit-Kaur GrewalJonathan R Fromm
Aug 17, 2020·Oncogenesis·Rana MhaidlyEls Verhoeyen
Jan 29, 2019·Pathology International·Ayako SakakibaraKei Kohno
May 31, 2020·Mycoses·Samuel OkurutDavid B Meya
Jul 21, 2017·Nature Reviews. Disease Primers·Shaji K KumarKenneth C Anderson
Nov 4, 2017·Wiener klinische Wochenschrift·Christiane ThallingerChristoph Zielinski
Jun 8, 2018·Clinical and Experimental Medicine·Amro Mohamed Sedky El-GhammazMohamad Ayed Mohamad
Jan 26, 2018·Asia-Pacific Journal of Clinical Oncology·Ziwei LiaoYangqiu Li
Jan 31, 2018·Histopathology·Ayako SakakibaraAkira Satou
May 8, 2019·Journal for Immunotherapy of Cancer·Sonja AlthammerKeith E Steele
Nov 26, 2020·Pathology International·Kanae OkadaShigeo Nakamura
Mar 7, 2021·Clinical and Experimental Immunology·Fang LiHongmei Jing
Apr 4, 2021·Pharmaceuticals·Laura JimbuMihnea Zdrenghea
Apr 4, 2021·European Journal of Immunology·Jan P NicolayEmilio Berti
Jun 22, 2021·Microbial Pathogenesis·Yalda Amiri HezaveMajide Shahabi
Aug 14, 2021·Cancer Medicine·Akira Satou, Shigeo Nakamura
Sep 18, 2021·The American Journal of Surgical Pathology·Tasuku KawanoAkira Satou